Association between DNA repair gene polymorphisms and risk of glioma: A systematic review and meta-analysis

Neuro-Oncology

Volumn 16, Issue 6, 2014, Pages 807-814

  Adel Fahmideh, Maral ^a   Schwartzbaum, Judith ^b   Frumento, Paolo ^a   Feychting, Maria ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b OHIO STATE UNIVERSITY   (United States)

Author keywords

brain neoplasm; DNA repair; glioma; meta analysis; single nucleotide polymorphism

Indexed keywords

EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1; XERODERMA PIGMENTOSUM GROUP D PROTEIN; XRCC1 PROTEIN;

ARTICLE; CANCER RISK; CANCER SUSCEPTIBILITY; DNA REPAIR; DNA REPAIR GENE; EXCISION REPAIR CROSS COMPLEMENTING GENE 1; GENE; GENETIC ANALYSIS; GENETIC ASSOCIATION; GENETIC SUSCEPTIBILITY; GENOTYPE; GLIOMA; HETEROZYGOTE; HOMOZYGOTE; HUMAN; MEDLINE; METHYLATED DNA PROTEIN CYSTEINE METHYLTRANSFERASE GENE; NICOTINAMIDE ADENINE DINUCLEOTIDE ADENOSINE DIPHOSPHATE RIBOSYLTRANSFERASE 1 GENE; SENSITIVITY ANALYSIS; SINGLE NUCLEOTIDE POLYMORPHISM; SYSTEMATIC REVIEW; XERODERMA PIGMENTOSUM GROUP D GENE; XRCC1 GENE; BRAIN TUMOR; GENETICS; META ANALYSIS; RISK FACTOR;

BRAIN NEOPLASMS; DNA REPAIR; GENETIC ASSOCIATION STUDIES; GLIOMA; HUMANS; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK FACTORS;

EID: 84901018665     PISSN: 15228517     EISSN: 15235866     Source Type: Journal    
DOI: 10.1093/neuonc/nou003     Document Type: Article

References (81)

1. Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10-29.
2. Kleihues PCW. Pathology and genetics of tumours of the nervous system. Lyon: IARC Press; 2000.
3. Dolecek TA, Propp JM, Stroup NE, et al. CBTRUS statistical report: primary brain and central nervous system tumors diagnosed in the United States in 2005-2009. Neuro Oncol. 2012;14 (Suppl 5):v1-49.
4. Ohgaki H, Kleihues P. Epidemiology and etiology of gliomas. Acta Neuropathol. 2005;109(1):93-108.
5. Schwartzbaum JA, Fisher JL, Aldape KD, et al. Epidemiology and molecular pathology of glioma. Nat Clin Pract Neurol. 2006;2(9): 494-503. quiz 491 p following 516.
6. Friedberg EC. DNA damage and repair. Nature. 2003;421(6921): 436-440.
7. Rajaraman P, Hutchinson A, Wichner S, et al. DNA repair gene polymorphisms and risk of adult meningioma, glioma, and acoustic neuroma. Neuro Oncol. 2010;12(1):37-48.
8. Bernstein C, Bernstein H, Payne CM, et al. DNA repair/pro-apoptotic dual-role proteins in five major DNA repair pathways: fail-safe protection against carcinogenesis. Mutat Res. 2002;511(2):145-178.
9. Christmann M, Tomicic MT, Roos WP, et al. Mechanisms of human DNA repair: an update. Toxicology. 2003;193(1-2):3-34.
10. Bethke L,Webb E, Murray A, et al. Comprehensive analysis of the role of DNA repair gene polymorphisms on risk of glioma. Hum Mol Genet. 2008;17(6):800-805.
11. Goode EL, Ulrich CM, Potter JD. Polymorphisms in DNA repair genes and associations with cancer risk. Cancer Epidemiol Biomarkers Prev. 2002;11(12):1513-1530.
12. Felini MJ, Olshan AF, Schroeder JC, et al. DNA repair polymorphisms XRCC1 and MGMT and risk of adult gliomas. Neuroepidemiology. 2007;29(1-2):55-58.
13. Liu Y. Association and interactions between DNA repair gene polymorphisms and adult glioma. Cancer Epidemiol Biomarkers Prev. 2009;18(1):204-214.
14. Yosunkaya E, Kucukyuruk B, Onaran I, et al. Glioma risk associates with polymorphisms of DNA repair genes, XRCC1 and PARP1. Br J Neurosurg. 2010;24(5):561-565.
15. Egger M, Davey Smith G, Schneider M, et al. Bias in meta-analysis detected by a simple, graphical test. BMJ. 1997;315(7109):629-634.
16. Wang LE, Bondy ML, Shen H, et al. Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 2004;64(16):5560-5563.
17. McKean-Cowdin R. Associations between polymorphisms in DNA repair genes and glioblastoma. Cancer Epidemiol Biomarkers Prevention. 2009;18(4):1118-1126.
18. Wrensch M, Kelsey KT, Liu M, et al. ERCC1 and ERCC2 polymorphisms and adult glioma. Neuro Oncol. 2005;7(4):495-507.
19. Chen P, Wiencke J, Aldape K, et al. Association of an ERCC1 polymorphism with adult-onset glioma. Cancer Epidemiol Biomarkers Prev. 2000;9(8):843-847.
20. Caggana M, Kilgallen J, Conroy JM, et al. Associations between ERCC2 polymorphisms and gliomas. Cancer Epidemiol Biomarkers Prev. 2001;10(4):355-360.
21. Kiuru A, Lindholm C, Heinavaara S, et al. XRCC1 and XRCC3 variants and risk of glioma and meningioma. J Neurooncol. 2008;88(2): 135-142.
22. Liu Y, Zhou K, Zhang H, et al. Polymorphisms of LIG4 and XRCC4 involved in the NHEJ pathway interact to modify risk of glioma. Hum Mutat. 2008;29(3):381-389.
23. Liu Y, Zhang H, Zhou K, et al. Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma. Carcinogenesis. 2007;28(9):1906-1913.
24. Semmler A, Simon M, Moskau S, et al. The methionine synthase polymorphism c.2756A.G alters susceptibility to glioblastoma multiforme. Cancer Epidemiol Biomarkers Prev. 2006; 15(11):2314-2316.
25. Sadetzki S, Flint-Richter P, Starinsky S, et al. Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol Biomarkers Prev. 2005;14(4):969-976.
26. Malmer BS, Feychting M, Lonn S, et al. Genetic variation in p53 and ATM haplotypes and risk of glioma and meningioma. J Neurooncol. 2007;82(3):229-237.
27. Yang P, Kollmeyer TM, Buckner K, et al. Polymorphisms in GLTSCR1 and ERCC2 are associated with the development of oligodendrogliomas. Cancer. 2005;103(11):2363-2372.
28. Zhou K, Liu Y, Zhang H, et al. XRCC3 haplotypes and risk of gliomas in a Chinese population: a hospital-based case-control study. Int J Cancer. 2009;124(12):2948-2953.
29. Zhou LQ, Ma Z, Shi XF, et al. Polymorphisms of DNA repair gene XRCC1 and risk of glioma: a case-control study in Southern China. Asian Pac J Cancer Prev. 2011;12(10):2547-2550.
30. Zhou K, Hu D, Lu J, et al. A genetic variant in the APE1/Ref-1 gene promoter-141T/G may modulate risk of glioblastoma in a Chinese Han population. BMC Cancer. 2011;11:1104.
31. Wang D, Hu Y, Gong H, et al. Genetic polymorphisms in the DNA repair gene XRCC1 and susceptibility to glioma in a Han population in northeastern China: a case-control study. Gene. 2012;509(2): 223-227.
32. Fan W. Possible association between genetic variants in the H2AFX promoter region and risk of adult glioma in a Chinese Han population. Journal of Neurosurgery. 2011;105(2):211-218.
33. Zhang N, Lin LY, Zhu LL, et al. ERCC1 polymorphisms and risk of adult glioma in a Chinese population: a hospital-based case-control study. Cancer Invest. 2012;30(3):199-202.
34. Salnikova LE, Zelinskaya NI, Belopolskaya OB, et al. Association study of xenobiotic detoxication and repair genes with malignant brain tumors in children. Acta Naturae. 2010;2(4):58-65.
35. Chang JS, Yeh RF, Wiencke JK, et al. Pathway analysis of single-nucleotide polymorphisms potentially associated with glioblastoma multiforme susceptibility using random forests. Cancer Epidemiol Biomarkers Prev. 2008;17(6):1368-1373.
36. Egan KM, Nabors LB, Olson JJ, et al. Rare TP53 genetic variant associated with glioma risk and outcome. J Med Genet. 2012; 49(7):420-421.
37. Hu XB, Feng Z, Fan YC, et al. Polymorphisms in DNA repair gene XRCC1 and increased genetic susceptibility to glioma. Asian Pac J Cancer Prev. 2011;12(11):2981-2984.
38. Biros E, Kalina I, Kohut A, et al. Allelic and haplotype frequencies of the p53 polymorphisms in brain tumor patients. Physiol Res. 2002; 51(1):59-64.
39. Idbaih A, Boisselier B, Marie Y, et al. TP53 codon 72 polymorphism, p53 expression, and 1p/19q status in oligodendroglial tumors. Cancer Genet Cytogenet. 2007;177(2):103-107.
40. Kafadar AM, Yilmaz H, Kafadar D, et al. C677T gene polymorphism of methylenetetrahydrofolate reductase (MTHFR) in meningiomas and high-grade gliomas. Anticancer Res. 2006;26(3B):2445-2449.
41. Malmer B, Feychting M, Lonn S, et al. p53 Genotypes and risk of glioma and meningioma. Cancer Epidemiol Biomarkers Prev. 2005; 14(9):2220-2223.
42. Chen DQ, Yao DX, Zhao HY, et al. DNA repair gene ERCC1 and XPD polymorphisms predict glioma susceptibility and prognosis. Asian Pac J Cancer Prev. 2012;13(6):2791-2794.
43. Ciara E, Piekutowska-Abramczuk D, Popowska E, et al. Heterozygous germ-line mutations in the NBN gene predispose to medulloblastoma in pediatric patients. Acta Neuropathol. 2010; 119(3):325-334.
44. Bethke L, Murray A, Webb E, et al. Comprehensive analysis of DNA repair gene variants and risk of meningioma. J Natl Cancer Inst. 2008;100(4):270-276.
45. Idbaih A, Boisselier B, Marie Y, et al. Influence of MDM2 SNP309 alone or in combination with the TP53 R72P polymorphism in oligodendroglial tumors. Brain Res. 2008;10(1198):16-20.
46. Cengiz S. Deoxy-ribonucleic acid repair genes XRCC 1 and XPD polymorphisms and brain tumor risk. Neurosciences. 2008;13(3): 227-232.
47. Rajaraman P, Melin BS, Wang Z, et al. Genome-wide association study of glioma and meta-analysis. Hum Genet. 2012;131(12): 1877-1888.
48. Shete S, Hosking FJ, Robertson LB, et al. Genome-wide association study identifies five susceptibility loci for glioma. Nat Genet. 2009; 41(8):899-904.
49. Wrensch M, Jenkins RB, Chang JS, et al. Variants in the CDKN2B and RTEL1 regions are associated with high-grade glioma susceptibility. Nat Genet. 2009;41(8):905-908.
50. Sanson M, Hosking FJ, Shete S, et al. Chromosome 7p11.2 (EGFR) variation influences glioma risk. Hum Mol Genet. 2011;20(14): 2897-2904.
51. Mohrenweiser HW, Carrano AV, Fertitta A, et al. Refined mapping of the three DNA repair genes, ERCC1, ERCC2, and XRCC1, on human chromosome 19. Cytogenet Cell Genet. 1989;52(1-2):11-14.
52. Wood RD. Nucleotide excision repair in mammalian cells. J Biol Chem. 1997;272(38):23465-23468.
53. Vermeulen W, de Boer J, Citterio E, et al. Mammalian nucleotide excision repair and syndromes. Biochem Soc Trans. 1997;25(1): 309-315.
54. Taylor RM, Thistlethwaite A, Caldecott KW. Central role for the XRCC1 BRCT I domain in mammalian DNA single-strand break repair. Mol Cell Biol. 2002;22(8):2556-2563.
55. Beneke R, Geisen C, Zevnik B, et al. DNA excision repair and DNA damage-induced apoptosis are linked to Poly(ADP-ribosyl)ation but have different requirements for p53. Mol Cell Biol. 2000;20(18): 6695-6703.
56. Infante J, Sanchez-Juan P, Mateo I, et al. Poly (ADP-ribose) polymerase-1 (PARP-1) genetic variants are protective against Parkinson's disease. J Neurol Sci. 2007;256(1-2):68-70.
57. Li C, Hu Z, Lu J, et al. Genetic polymorphisms in DNA baseexcision repair genes ADPRT, XRCC1, and APE1 and the risk of squamous cell carcinoma of the head and neck. Cancer. 2007; 110(4):867-875.
58. Li C, Liu Z, Wang LE, et al. Genetic variants of the ADPRT, XRCC1 and APE1 genes and risk of cutaneous melanoma. Carcinogenesis. 2006; 27(9):1894-1901.
59. Zarghooni M, Bartels U, Lee E, et al. Whole-genome profiling of pediatric diffuse intrinsic pontine gliomas highlights platelet-derived growth factor receptor alpha and poly (ADP-ribose) polymerase as potential therapeutic targets. J Clin Oncol. 2010; 28(8):1337-1344.
60. Megnin-Chanet F, Bollet MA, Hall J. Targeting poly(ADP-ribose) polymerase activity for cancer therapy. Cell Mol Life Sci. 2010; 67(21):3649-3662.
61. Annunziata CM, O'Shaughnessy J. Poly (ADP-ribose) polymerase as a novel therapeutic target in cancer. Clin Cancer Res. 2010;16(18): 4517-4526.
62. Plummer R, Jones C, Middleton M, et al. Phase I study of the poly(ADP-ribose) polymerase inhibitor, AG014699, in combination with temozolomide in patients with advanced solid tumors. Clin Cancer Res. 2008;14(23):7917-7923.
63. Gartner EM, Burger AM, Lorusso PM. Poly(adp-ribose) polymerase inhibitors: a novel drug class with a promising future. Cancer J. 2010;16(2):83-90.
64. Burkle A. Physiology and pathophysiology of poly(ADP-ribosyl)ation. Bioessays. 2001;23(9):795-806.
65. Han J, Hankinson SE, De Vivo I. Polymorphisms in O6-methylguanine DNA methyltransferase and endometrial cancer risk. Carcinogenesis. 2006;27(11):2281-2285.
66. Zhang M, Huang WY, Andreotti G, et al. Variants of DNA repair genes and the risk of biliary tract cancers and stones: a population-based study in China. Cancer Epidemiol Biomarkers Prev. 2008;17(8): 2123-2127.
67. Huang WY, Olshan AF, Schwartz SM, et al. Selected genetic polymorphisms in MGMT, XRCC1, XPD, and XRCC3 and risk of head and neck cancer: a pooled analysis. Cancer Epidemiol Biomarkers Prev. 2005;14(7):1747-1753.
68. Stern MC, Conti DV, Siegmund KD, et al. DNA repair single-nucleotide polymorphisms in colorectal cancer and their role as modifiers of the effect of cigarette smoking and alcohol in the Singapore Chinese Health Study. Cancer Epidemiol Biomarkers Prev. 2007;16(11): 2363-2372.
69. Sharma S, Salehi F, Scheithauer BW, et al. Role of MGMT in tumor development, progression, diagnosis, treatment and prognosis. Anticancer Res. 2009;29(10):3759-3768.
70. Pegg AE, Fang Q, Loktionova NA. Human variants of O6-alkylguanine-DNA alkyltransferase. DNA Repair (Amst). 2007; 6(8):1071-1078.
71. Rasimas JJ, Kanugula S, Dalessio PM, et al. Effects of zinc occupancy on human O6-alkylguanine-DNA alkyltransferase. Biochemistry. 2003;42(4):980-990.
72. Fang Q, Kanugula S, Pegg AE. Function of domains of human O6-alkylguanine-DNA alkyltransferase. Biochemistry. 2005;44(46): 15396-15405.
73. Wei X, Chen D, Lv T. A functional polymorphism in XRCC1 is associated with glioma risk: evidence from a meta-analysis. Mol Biol Rep. 2013;40(1):567-572.
74. Sun JY, Zhang CY, Zhang ZJ, et al. Association between XRCC1 gene polymorphisms and risk of glioma development: a meta-analysis. Asian Pac J Cancer Prev. 2012;13(9):4783-4788.
75. Jiang L, Fang X, Bao Y, et al. Association between the XRCC1 polymorphisms and glioma risk: a meta-analysis of case-control studies. PLoS One. 2013;8(1):e55597.
76. Jacobs DI, Bracken MB. Association between XRCC1 polymorphism 399 G-.A and glioma among Caucasians: a systematic review and meta-analysis. BMC Med Genet. 2012; doi: 10.1186/1471-2350-13-97.
77. Yu H, Ma H, Yin M, Wei Q. Association between PARP-1 V762A polymorphism and cancer susceptibility: a meta-analysis. Genet Epidemiol. 2012;36(1):56-65.
78. Li Y, Gu S,Wu Q, et al. No association of ERCC1 C8092A and T19007C polymorphisms to cancer risk: a meta-analysis. Eur J Hum Genet. 2007;15(9):967-973.
79. Zhang L, Wang J, Xu L, et al. Nucleotide excision repair gene ERCC1 polymorphisms contribute to cancer susceptibility: a meta-analysis. Mutagenesis. 2012;27(1):67-76.
80. Walsh KM, Anderson E, Hansen HM, et al. Analysis of 60 reported glioma risk SNPs replicates published GWAS findings but fails to replicate associations from published candidate-gene studies. Genet Epidemiol. 2013;37(2):222-228.
81. Rothman K. No adjustments are needed for multiple comparisons. Epidemiology. 1990;1(1):43-46.